REAL-WORLD DATA (RWD) / REAL-WORD EVIDENCE (RWE) INSIGHTS

RWD/RWE VIDEOS

Healthcare decision-making is evolving fast. Discover how AI, RWE, and changing HTA frameworks are influencing pricing, patient engagement, and market access.

Discover how patient-led registries are becoming a practical source of real-world evidence, drug repurposing insight, and smarter trial design.

PMCF costs are straining device budgets. Discover how AI-assisted review and real-world data from other regions can help you meet EU requirements more efficiently.

A candid look at balancing resource constraints with rigorous clinical strategy to earn trust, reimbursement, and real growth.

RWD/RWE RESOURCES

  • Real-World Data Vs. Real-World Evidence

    Unearth the ways real-world data (RWD) and real-world evidence (RWE) in clinical R&D can be used to provide additional validation for new therapies and drugs regarding their efficacy, safety, and value.

  • Real-World Evidence - Where Are We Now?

    Notwithstanding ongoing confusion over the concepts of “real-world data” and “real-world evidence” in 2022, more than 5 years after the passage of the 21st Century Cures Act, the FDA continues to evaluate such data and evidence as it considers regulatory decisions.

  • Top HEOR Trends

    Real-world evidence (RWE) offers insights into the effectiveness of medical treatments in everyday settings, with various stakeholders utilize RWE to enhance healthcare.

  • Using RWE To Get To Insights And Action — Faster

    Delve into three examples that vividly showcase the formidable power of real-world evidence from the early stages of drug development through clinical trials and commercialization.

  • Automated Evidence Generation For Regulatory-Grade RWD

    Global regulatory agencies increasingly adopt Real-World Evidence, demanding higher data quality and automated AI-driven platforms to meet evolving standards and improve drug development pathways.

  • Could ePRO Be The New Standard In Health Reimbursement?

    Recently, early-phase protocols have been collecting patient-reported outcomes (PROs) not only to get regulatory approval but to demonstrate value to public and private payers.

  • Accelerate Recruitment With Real-Time, High-Fidelity Data

    With expanded access to a wider range of demographics and billions of additional Mx and prescription Rx encounters, discover how Pulse can optimize the pool of potential trial participants.